Analysed SERES THERAPEUTICS INC (MCRB:NASDAQ) News Sources
Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
02-03-2026
yahoo.com
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
12-03-2026
yahoo.com
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
20-04-2026
yahoo.com
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
04-05-2026
yahoo.com
Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
05-05-2026
yahoo.com
Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
12-05-2026
yahoo.com
Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027
05-06-2026
yahoo.com
What is the current price of SERES THERAPEUTICS INC (MCRB:NASDAQ)?
The current price of SERES THERAPEUTICS INC (MCRB:NASDAQ) is $6.425.
SERES THERAPEUTICS INC (MCRB:NASDAQ) absolute price change since previous trading day?
The absolute price change of SERES THERAPEUTICS INC (MCRB:NASDAQ) since the previous trading day is $0.455.
SERES THERAPEUTICS INC (MCRB:NASDAQ) percentage price change since previous trading day?
The percentage price change of SERES THERAPEUTICS INC (MCRB:NASDAQ) since the previous trading day is 7.6214%.
What is the most recent average sentiment score for SERES THERAPEUTICS INC (MCRB:NASDAQ)?
The most recent average sentiment score for SERES THERAPEUTICS INC (MCRB:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for SERES THERAPEUTICS INC (MCRB:NASDAQ)?
The most recent sentiment for SERES THERAPEUTICS INC (MCRB:NASDAQ) is .
SEC-8K** Filing Available For SERES THERAPEUTICS INC (MCRB:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.